Targeting a protein to boost immune memory against brain tumors
Fgl2 neutralizing therapy for inducing tumor specific brain resident immune memory against CNS tumor relapse
This study is testing a new treatment for glioblastoma that uses special T cells to help your immune system fight the cancer better after chemotherapy, with the hope of preventing it from coming back.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tx Md Anderson Can Ctr NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project ID | NIH-10874548 on NIH RePORTER |
What this research studies
This research investigates a new therapy that neutralizes a protein called Fgl2, which suppresses the immune response in patients with glioblastoma (GBM). By administering T cells that are designed to target Fgl2 after standard chemotherapy, the goal is to stimulate the brain's immune system to create memory T cells that can recognize and eliminate tumor cells. This approach aims to prevent the recurrence of GBM by enhancing the body's own defenses against the cancer. Patients may be monitored for their immune response and tumor progression throughout the treatment.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with glioblastoma who have undergone standard chemotherapy.
Not a fit: Patients with non-brain tumors or those who have not received prior chemotherapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved long-term outcomes for patients with glioblastoma by reducing the chances of tumor recurrence.
How similar studies have performed: Previous research has shown promise in using immune therapies to target brain tumors, suggesting that this approach may be effective.
Where this research is happening
Houston, United States
- University of Tx Md Anderson Can Ctr — Houston, United States (Active)
Researchers
- Principal investigator: Li, Shulin — University of Tx Md Anderson Can Ctr
- Study coordinator: Li, Shulin
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.